Gain insight on pharma’s tendency to pick licensing deals over M&A when refuelling the pipelines, and understand how is pharma making up its shopping list: which type of assets are the most coveted? How is the roaring competition for innovative oncology assets influencing valuations and boosting early-stage deals? Will the global turn towards infectious and viral diseases induced by the COVID-19 crisis continue to be the overriding priority?

Jonas Jendi - Industrifonden
Melanie Senior - Informa
Paul Van Der Horst - Galapagos

Continue your tour